Incorporating founder virus information in vaccine field trials
From MaRDI portal
Publication:3459936
DOI10.1111/BIOM.12277zbMATH Open1390.62255OpenAlexW2133906271WikidataQ36509005 ScholiaQ36509005MaRDI QIDQ3459936FDOQ3459936
Authors: Dean A. Follmann, Chiung-Yu Huang 
Publication date: 11 January 2016
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: http://europepmc.org/articles/pmc4729213
Recommendations
- Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation
- Sieve analysis using the number of infecting pathogens
- Sensitivity Analysis for the Assessment of Causal Vaccine Effects on Viral Load in HIV Vaccine Trials
- Statistical Methods for Assessing Differential Vaccine Protection Against Human Immunodeficiency Virus Types
- Simultaneous inferences of HIV vaccine effects on viral load, CD4 cell counts, and antiretroviral therapy initiation in phase 3 trials
General nonlinear regression (62J02) Applications of statistics to biology and medical sciences; meta analysis (62P10)
Cites Work
- Asymptotic Statistics
- Proportional hazards models with continuous marks
- The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy
- The Analysis of Failure Times in the Presence of Competing Risks
- On Profile Likelihood
- Title not available (Why is that?)
- Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization
- Design and analysis of vaccine studies
- Augmented Designs to Assess Immune Response in Vaccine Trials
- Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials
Cited In (4)
This page was built for publication: Incorporating founder virus information in vaccine field trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3459936)
